Looking back over the past 12 months, Information Technology was heads and shoulders the best-performing sector.

Shaw and Partners Chief Investment Officer Martin Crabbe outlines a four-part investment strategy, focusing on growth, financial conditions, central bank policy and valuation. He notes that ...

Mesoblast specialises in developing medicines that treat severe inflammatory conditions. Their technology is being applied to conditions like chronic heart failure and chronic low back pain.

Larvotto Resources (ASX:LRV) has reported final results from its reverse circulation drilling program at the Clarks Gully deposit, which is part of the company's Hillgrove Gold-Antimony Project in ...

DigiCo REIT (ASX:DGT), a new real estate investment trust focused on data centres, has made its debut on the ASX. This was Australia's largest initial public offering (IPO) in six years, since ...

This week saw a flurry of activity in the small-cap market, with exciting developments in biotech, energy, and litigation funding. Here’s a snapshot of the stocks making headlines. INOVIQ (ASX ...

Dr Shane Oliver, Head of Investment Strategy & Chief Economist at AMP, discusses developments in investment markets over the past week, economic activity trackers, major global economic events and ...

Silex Systems (ASX:SLX) specialises in laser-based technology for uranium enrichment. Its proprietary SILEX (Separation of Isotopes by Laser Excitation) process uses lasers to selectively excite ...

INOVIQ (ASX:IIQ) has completed a proof-of-concept (POC) study showing that exosomes—tiny vesicles released from cells—can be "weaponised" to target and kill breast cancer cells. The process ...

The US stock market has shown mixed results overnight. The Dow Jones Industrial Average fell for an eighth consecutive session—its longest losing streak since 2018. In contrast, the Nasdaq ...

US stocks struggled last week as concerns over inflation and US president-elect Donald Trump’s tariff plans weighed on sentiment. The Dow slipped 0.2%, the S&P 500 was flat, and the Nasdaq ...

Dr David Stamler - CEO - Alterity Therapeutics Limited (ASX:ATH) is developing first-in-class therapies to treat neurodegenerative disease. The company's lead drug candidate, ATH434, has ...